Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

My previous session
Most popular
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

EUROPE MARKETS: European Stocks Gain, But AstraZeneca Slumps

share with twitter share with LinkedIn share with facebook
share via e-mail
05/27/2014 | 06:19pm CEST

By Carla Mozee, MarketWatch

LONDON (MarketWatch) -- European stocks advanced Tuesday, with the pan-European benchmark hanging at a six-year high, but AstraZeneca PLC shares were stuck in the red after Pfizer Inc. officially walked away from its pursuit of the British drug maker.

The Stoxx Europe 600 index closed up 0.2% at 344.47 after a 0.6% run higher on Monday following European parliamentary elections.

European markets were additionally buoyed by "further dovish remarks" by European Central Bank President Draghi who "highlighted the risk of a negative spiral between low inflation, falling inflation expectations and credit for the euro area," said Guillermo Felices at Barclays asset allocation research, in a note Tuesday. "We retain our call that the ECB will cut its policy rate and/or announce targeted liquidity measures to support bank lending," at the Governing Council's meeting on June 5.

On Tuesday, Belgium, the first euro-zone country to report inflation data for May, said growth in consumer prices dropped to the lowest level in more than four years, with an inflation rate of 0.36%. The Belgium BEL 20 stock index rose 0.3% to 3,153.97.

There were strong gains in the European parliamentary elections, which ended Sunday, for anti-European Union and far-right parties, reflecting widespread voter frustration over economic austerity and lackluster growth. Overall, centrist, pro-European parties are poised to hold a majority of the 751 seats in the legislature.

Investors "took the electoral success in stride. The duopoly of the center-right and center-left will persist and still dominate the EU parliament," said currency analysts at Brown Brothers Harriman in a report Tuesday. "This will likely become clearer when the new [European Commission] president and commission are put together," they said. "The anti-EU vote is far from a unitary bloc. They are a disparate collection of national parties."

Germany's DAX 30 index turned higher by 0.5% to 9,940.82, and France's CAC 40 index moved up 0.1% to 4,529.75.

Aveva Group surged 8.8%, the best performer on the Stoxx 600, after the British engineering data and design IT systems company posted a 9% rise in 2014 pretax profit.

Trading resumed in the U.K. after Monday's Bank holiday. The FTSE 100 rose 0.4% to 6,844.94, led by InterContinental Hotels Group . Its shares climbed 3.1% after the owner of Holiday Inns, Crowe Plaza and other hospitality chains reportedly said over the weekend it rejected a GBP6 billion bid ($10.12 billion) from an unnamed U.S. company.

But AstraZeneca PLC (>> AstraZeneca plc) dropped 1.8% after Pfizer Inc. (>> Pfizer Inc.) officially walked away from its offer to buy the British drug maker for $120 billion.

The increased bid came four weeks from the confirmation of Pfizer's first offer, which was also rejected by AstraZeneca. U.K. takeover rules gave the firms until Monday to enter takeover discussions. Société Générale cut its rating on AstraZeneca to sell from hold, and Panmure Gordon lowered its price target on the company, according to Dow Jones Newswires.

Meanwhile, Russian stocks were knocked lower as dozens of pro-Russian separatists were killed by Ukrainian forces in heavy fighting at Donetsk International Airport. On Sunday, pro-Europe chocolate baron Petro Poroshenko was elected as Ukraine's new president. The blue-chips MICEX index fell 2.5%, and the RTS index gave up 2.9%.

The political crisis in Ukraine slashed Russian lender VTB Bank's first-quarter profit by 98% to 400 million rubles ($11.7 million).

Italy's FTSE MIB index tilted lower by 0.4% to 21,403.55 after swinging between gains and losses. The index had been higher following a report that consumer confidence in the country in May rose to its highest level since January 2010.The MIB index on Monday rallied 1.8%, led by bank stocks, after Italian Prime Minister Matteo Renzi's center-left Democratic Party defeated a challenge from a euroskeptic party headed by comedian Beppe Grillo.

More must-reads from MarketWatch:

Belgian data is bad omen for the euro zone

Dividend-yielding stocks are paying off now

To beat insomnia, say good night to this first

Stocks mentioned in the article : AstraZeneca plc, Pfizer Inc.
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA -0.90% 6052 Delayed Quote.18.18%
AVEVA GROUP PLC 0.31% 2620 Delayed Quote.-5.24%
BEL 20 -0.45% 3801.93 Real-time Quote.-4.00%
CAC 40 -0.04% 5412.32 Real-time Quote.1.92%
DAX -0.53% 12358.74 Delayed Quote.-4.33%
FTSE 100 INDEX 0.28% 7234.11 End-of-day quote.-5.90%
MILAAN-FTSE/MIB 0.22% 22483.6 End-of-day quote.2.67%
RUSLAND-RTS 0.27% 1059.76 End-of-day quote.-8.20%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ASTRAZENECA
08/09ASTRAZENECA : Ex-dividend day for interim dividend
08/08Merck's Zepatier price cut lands it co-exclusive status on Express Scripts 20..
08/08ASTRAZENECA : Settles Texas Drug Marketing Litigation -- Bloomberg
08/03Merck, AstraZeneca Get EMA Orphan Designation for Selumetinib
08/03ASTRAZENECA : Selumetinib granted orphan designation in Europe for neurofibromat..
08/03ASTRAZENECA : EMA grants OD for selumetinib in NF1
08/01More drugmakers build Brexit stockpiles as EU agency faces exodus
07/27ASTRAZENECA : Imfinzi receives positive EU CHMP opinion for locally-advanced, un..
07/27ASTRAZENECA : Imfinzi Receives EU Marketing Recommendation
More news
News from SeekingAlpha
08/11Eli Lilly Is An Attractive Buy For 2018 
08/09BeiGene launches late-stage study of tislelizumab in first-line lung cancer 
08/08AstraZeneca goes ex-dividend tomorrow 
08/08AstraZeneca to settle two lawsuits in Texas for $110M 
08/07JOHNSON & JOHNSON : Headline Risk But Business Solid 
Financials ($)
Sales 2018 22 224 M
EBIT 2018 5 355 M
Net income 2018 2 201 M
Debt 2018 14 768 M
Yield 2018 3,55%
P/E ratio 2018 41,51
P/E ratio 2019 34,39
EV / Sales 2018 5,11x
EV / Sales 2019 4,81x
Capitalization 98 768 M
Duration : Period :
AstraZeneca Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 76,1 $
Spread / Average Target -1,6%
EPS Revisions
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA18.18%98 768
JOHNSON & JOHNSON-6.42%351 898
PFIZER13.00%239 832
NOVARTIS-0.87%211 970
ROCHE HOLDING LTD.-3.39%209 687
MERCK AND COMPANY17.42%177 560